Jason Coloma

We are pleased to announce positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidney disease (AMKD). Read the full announcement below and tune into our conference call at 8 am ET. ir.mazetx.com/news-releases/…

This #InternationalWomensDay, we’re celebrating the women of Maze whose ideas, leadership and dedication help move our science and mission forward every day. We’re proud to foster a workplace where women are supported, empowered and able to thrive. Because when women rise, we all go further together.

BMD : osteoporosis :: proteinuria : CKD Optimistic that #osteoporosis will be the next kidney disease (from a biotech perspective) in 5 years, with a rapidly evolving therapeutic arsenal coming soon Clinicians treat osteopenia (which affects >40M in US alone!) today with monitoring, repeat DEXA scans, but woefully little intervention. Today's therapeutic arsenal is cheap drugs: anti-resorptive alendronate is <$10/month, like anti-hypertensives are in CKD... But a change in what @US_FDA considers a valid surrogate endpoint (is BMD the new proteinuria?) could lead to a whirlwind of development activity as we saw in IgAN and other CKD subsets. New mechanisms, new modalities, perhaps more anabolics... fda.gov/drugs/drug-saf… If you're building something new in osteoporosis, please reach out! @a16zBioHealth

In recognition of #BlackHistoryMonth, we welcomed Maze patient advisory committee member and #APOL1 #kidneydisease warrior Sharron Rouse for a powerful discussion on how APOL1 advocacy groups can better support patients, highlighting the importance of education, community, and patient voices. Hope begins with awareness and strong advocacy can transform the patient journey by empowering individuals, strengthening communities, and paving the way for meaningful change. Learn more about Sharron's patient advocacy group @kkidneys here: kindnessforkidneys.org

@MazeInBiotech @anirvan0419 Always appreciate the chance to step back and reflect on the road so far. Moments like this are a reminder that the most important work is still ahead for patients. Excited for what we’re building next. Thanks @anirvan0419 for the thoughtful conversation.

On the Let’s Talk About That podcast, our CEO Jason Coloma sat down with @anirvan0419 to reflect on Maze’s journey from its earliest days through its IPO. He also shared how Maze anticipates growing over the next several years and continuing to build for durable impact through its #precisionmedicine approach. Listen here: open.spotify.com/episode/7dCJGG…

Packed house for @MazeInBiotech $MAZE CEO @jcmazer as he provides a pipeline update and look ahead at milestones for the yr at #JPM26; you can view the presentation here: ir.mazetx.com/static-files/6…

As we close out 2025, we’re taking a moment to reflect on what has truly made it meaningful. This year was filled with important milestones, deeper partnerships with the patient community, and continued progress driven by science. We’re grateful to everyone who has been part of this journey and excited for what’s ahead in 2026!

Our president, head of research and development, and chief medical officer Harold Bernstein, M.D., Ph.D., recently shared the Maze story at the BioScience Forum, a monthly gathering for the biotech community in the San Francisco Bay Area. We appreciated the opportunity to connect with peers and discuss Maze’s mission and scientific approach, including how our Compass platform leverages variant functionalization to design #precisionmedicines that account for the genetic drivers of disease. biosf.org

On #PKUAwarenessDay, Maze supports @NPKUA_info, PKU patients, and families. We honor the #phenylketonuria community and recognize the strength, resilience, and advocacy of individuals and families navigating this rare metabolic disorder. At Maze, we’re dedicated to advancing meaningful options for people living with PKU through our investigational program, MZE782, an oral, small-molecule targeting the solute transporter SLC6A19, designed with the potential to deliver a best-in-class therapy for individuals with PKU. Learn more about PKU and ways to support the community through @NPKUA_info here: npkua.org

Modern science workflows are changing quickly: enabled by new tools, datasets, and AI models capable of advanced reasoning. The @ChanZuckerberg @czbiohub teams were among the earliest groups to recognize this. Since launching in 2015, they set an audacious goal: to contribute tools and infrastructure that could help scientists cure, prevent, or manage all human disease by the end of the century. It was a tremendous pleasure to host Priscilla Chan and Mark Zuckerberg to discuss their vision for the future of @officialbiohub, how they are selecting their 10-15 yr "grand challenges", and why they think "virtual cells" could become a new kind of model organism for a wide range of biological research. Thank you Priscilla and Mark for joining @et @bhorowitz and I for this energizing conversation! @a16z @a16zBioHealth

Mark Zuckerberg and Priscilla Chan say virtual cells could change how science takes risk, letting researchers test bold ideas in simulation before entering the wet lab. “The promise of being able to do virtual biology… is you can actually take on riskier ideas.” “If you had a virtual cell model… you could actually then start testing it and tinkering on the computational side… and actually see if there is promise doing the experiments in silico before you make the time and money investment in the wet lab.”

We're excited to be at this year’s @ASNKidney’s #KidneyWk! This week, we will present additional pharmacokinetic data from our Phase 1 clinical trial of MZE782, research supporting inhibition of SLC6A19 to slow disease progression in #chronickidneydisease and data supporting the scientific foundation and therapeutic rationale for MZE829. Read more: ir.mazetx.com/news-releases/…

@MikeHuckman Thank you Mike. You are the best!

Client 👇

Our CEO Jason Coloma joined @SullyCNBC on @CNBC’s @PowerLunch to discuss Maze’s recent progress and how we’re translating human genetics into new therapies across our pipeline. Chronic kidney disease remains a devastating condition with limited treatment options, affecting millions of patients and families worldwide. At Maze, we’re committed to advancing novel #smallmolecule #precisionmedicines designed to address the underlying drivers of #kidneydisease and metabolic disorders in meaningful ways. Watch the full interview: cnbc.com/video/2025/10/…

Welcome Hervé Hoppenot as Chairman of our Board of Directors, succeeding Charles Homcy, M.D., who will remain on the Board. Hervé’s decades of experience will be invaluable as we approach major milestones in 2026. ir.mazetx.com/news-releases/…

We are pleased to announce an oversubscribed private placement of $150M today to further advance our pipeline of small molecule precision medicines for patients with kidney and metabolic diseases. Read the full announcement: ir.mazetx.com/news-releases/…

Congrats to the @MazeInBiotech team on exciting new clinical data + an over-subscribed $150m private placement 💡 A rare case of healthy volunteer data providing clear de-risking of not only the drug's safety, but also its target engagement and therapeutic MoA (via urinary phenylalanine excretion observable in healthy trial participants)! "We look forward to advancing MZE782 into Phase 2 studies in both PKU and CKD in 2026" 🦅 And, validation for the increasingly endangered but beautiful species that are productive, multi-asset biotech platforms: "MZE782 is the third clinical program to come out of our Compass platform, demonstrating our ability to harness the power of human genetics to develop small molecule precision medicines designed to transform the lives of patients with kidney and metabolic diseases.” ir.mazetx.com/news-releases/…

We're thrilled to announce positive clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule SLC6A19 inhibitor. MZE782 has potential to be a best-in-class therapy for patients with #phenylketonuria (PKU), an inherited metabolic disorder, and a first-in-class therapy for patients with chronic #kidneydisease. Read the full announcement: ir.mazetx.com/news-releases/…